![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LIN28A |
Gene summary for LIN28A |
![]() |
Gene information | Species | Human | Gene symbol | LIN28A | Gene ID | 79727 |
Gene name | lin-28 homolog A | |
Gene Alias | CSDD1 | |
Cytomap | 1p36.11 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9H9Z2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79727 | LIN28A | HCC1 | Human | Liver | HCC | 1.17e-09 | 7.06e-01 | 0.5336 |
79727 | LIN28A | HCC2 | Human | Liver | HCC | 3.10e-11 | 7.14e-01 | 0.5341 |
79727 | LIN28A | HCC5 | Human | Liver | HCC | 8.91e-07 | 4.16e-01 | 0.4932 |
79727 | LIN28A | S015 | Human | Liver | HCC | 2.74e-02 | 1.69e-01 | 0.2375 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
GO:000218122 | Liver | HCC | cytoplasmic translation | 132/7958 | 148/18723 | 9.09e-33 | 5.76e-30 | 132 |
GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
GO:004427021 | Liver | HCC | cellular nitrogen compound catabolic process | 303/7958 | 451/18723 | 9.76e-27 | 3.64e-24 | 303 |
GO:004670021 | Liver | HCC | heterocycle catabolic process | 299/7958 | 445/18723 | 2.07e-26 | 7.29e-24 | 299 |
GO:190136121 | Liver | HCC | organic cyclic compound catabolic process | 325/7958 | 495/18723 | 6.52e-26 | 2.18e-23 | 325 |
GO:001943921 | Liver | HCC | aromatic compound catabolic process | 309/7958 | 467/18723 | 1.56e-25 | 4.94e-23 | 309 |
GO:000640121 | Liver | HCC | RNA catabolic process | 201/7958 | 278/18723 | 3.88e-24 | 1.02e-21 | 201 |
GO:003465521 | Liver | HCC | nucleobase-containing compound catabolic process | 273/7958 | 407/18723 | 4.84e-24 | 1.23e-21 | 273 |
GO:000641722 | Liver | HCC | regulation of translation | 287/7958 | 468/18723 | 8.79e-17 | 8.08e-15 | 287 |
GO:004572712 | Liver | HCC | positive regulation of translation | 97/7958 | 136/18723 | 8.51e-12 | 3.55e-10 | 97 |
GO:003425022 | Liver | HCC | positive regulation of cellular amide metabolic process | 110/7958 | 162/18723 | 5.14e-11 | 1.92e-09 | 110 |
GO:00311231 | Liver | HCC | RNA 3'-end processing | 81/7958 | 116/18723 | 2.27e-09 | 6.32e-08 | 81 |
GO:000974322 | Liver | HCC | response to carbohydrate | 149/7958 | 253/18723 | 9.55e-08 | 1.89e-06 | 149 |
GO:003428422 | Liver | HCC | response to monosaccharide | 131/7958 | 225/18723 | 1.32e-06 | 1.91e-05 | 131 |
GO:000974622 | Liver | HCC | response to hexose | 126/7958 | 219/18723 | 4.81e-06 | 6.06e-05 | 126 |
GO:00319291 | Liver | HCC | TOR signaling | 78/7958 | 126/18723 | 8.49e-06 | 9.97e-05 | 78 |
GO:000974912 | Liver | HCC | response to glucose | 121/7958 | 212/18723 | 1.24e-05 | 1.39e-04 | 121 |
GO:003105021 | Liver | HCC | dsRNA processing | 38/7958 | 54/18723 | 3.15e-05 | 3.21e-04 | 38 |
GO:007091821 | Liver | HCC | production of small RNA involved in gene silencing by RNA | 38/7958 | 54/18723 | 3.15e-05 | 3.21e-04 | 38 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LIN28A | SNV | Missense_Mutation | c.624G>C | p.Gln208His | p.Q208H | Q9H9Z2 | protein_coding | deleterious_low_confidence(0.01) | benign(0.364) | TCGA-B5-A0JN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | SD | |
LIN28A | SNV | Missense_Mutation | c.387N>A | p.Met129Ile | p.M129I | Q9H9Z2 | protein_coding | tolerated(0.19) | benign(0) | TCGA-B5-A0JR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LIN28A | SNV | Missense_Mutation | novel | c.422A>G | p.Asn141Ser | p.N141S | Q9H9Z2 | protein_coding | deleterious(0) | benign(0.175) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
LIN28A | SNV | Missense_Mutation | novel | c.322C>A | p.Arg108Ser | p.R108S | Q9H9Z2 | protein_coding | tolerated(0.06) | probably_damaging(0.998) | TCGA-05-4396-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
LIN28A | SNV | Missense_Mutation | rs759205887 | c.194N>T | p.Ala65Val | p.A65V | Q9H9Z2 | protein_coding | tolerated(0.09) | benign(0.015) | TCGA-55-1592-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
LIN28A | SNV | Missense_Mutation | c.265N>A | p.Glu89Lys | p.E89K | Q9H9Z2 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-55-8510-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
LIN28A | SNV | Missense_Mutation | novel | c.335C>T | p.Pro112Leu | p.P112L | Q9H9Z2 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-86-8076-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | etoposide | CR |
LIN28A | SNV | Missense_Mutation | novel | c.241N>G | p.Met81Val | p.M81V | Q9H9Z2 | protein_coding | tolerated(0.05) | probably_damaging(0.978) | TCGA-NJ-A4YQ-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LIN28A | SNV | Missense_Mutation | rs748777822 | c.563C>A | p.Pro188Gln | p.P188Q | Q9H9Z2 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-37-4130-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
LIN28A | SNV | Missense_Mutation | rs768587147 | c.331G>A | p.Gly111Arg | p.G111R | Q9H9Z2 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-51-6867-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |